About us
Momentum Biotechnologies, founded in 2014, is a drug discovery partner providing specialized, cutting-edge mass spectrometry technologies to biopharmaceutical clients across the globe. Through a diverse array of services, including affinity-selection mass spectrometry (ASMS), covalent binding assays, proteomics / chemoproteomics, and small-molecule analysis, Momentum helps clients identify, validate, and characterize therapeutic leads, accelerating critical drug discovery efforts. Thanks to their proven workflows, state-of-the-art facilities, and extensive mass spectrometry experience, Momentum is uniquely positioned to deliver rapid, reliable answers to a wide range of pressing research questions. In 2025, Momentum expanded to the European market, where it operates as
OmicScouts, a Momentum Biotechnologies Company. For more information, please visit
www.momentum.bio.